Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M

FATE THERAPEUTICS INC

Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.
Stockholders approved increase in authorized common shares from 250M to 350M, effective May 29, 2025.
Second amendment to 2022 stock plan approved, adding 7M shares to the reserve.
Dr. Shefali Agarwal and Dr. Bahram Valamehr re-elected Class III directors; E&Y ratified as auditor.
Non-binding say-on-pay passed with ~68.9M for (92.4% of votes cast); frequency set at 1 year.

item 5.02 item 5.07 item 5.03 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Timothy P. Coughlin

Director

FATE · FATE THERAPEUTICS INC

Effective: 2025-05-29
Successor: Matthew Abernethy
Filed: May 30, 2025, 7:59 PM ET

Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.

Appointed

Matthew Abernethy

Class III Director

FATE · FATE THERAPEUTICS INC

Effective: 2025-05-29
Filed: May 30, 2025, 7:59 PM ET

appointed Matthew Abernethy to the Board to serve as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy P. Coughlin departed as Director at FATE THERAPEUTICS INC.

Action: term ended
Role: Director

Exact text from the filing

Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Abernethy was appointed as Class III Director at FATE THERAPEUTICS INC.

Action: appointed
Role: Class III Director

Exact text from the filing

appointed Matthew Abernethy to the Board to serve as a Class III director

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

FATE THERAPEUTICS INC: Increased authorized shares of Common Stock from 250,000,000 to 350,000,000 (effective 2025-05-29).

Change: charter amendment
Effective: 2025-05-29

Exact text from the filing

to increase the number of authorized shares of Common Stock from 250,000,000 shares to 350,000,000 shares

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-25-132301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.